Glucagon in the Treatment of Paget's Disease of Bone

Glucagon given by intravenous infusion at a dosage of 0·2 to 0·8 mg/hour to four patients with Paget''s disease of bone resulted in a dramatic fall in plasma alkaline phosphatase. This was associated with a fall in 24-hour urinary calcium and in total urinary hydroxyproline excretion and a marked relief of bone pain.Glucagon may induce these changes by three possible mechanisms: (1) by stimulating release of calcitonin; (2) by a direct action of the hormone on bone; and (3) by stimulation of certain bone pyrophosphatases, thus altering the local mechanisms controlling the rate of bone formation and resorption.     

Day-care surgery in British Columbia: a 7-year experience (1968-74).

Twenty-eight patients with symptomatic Paget''s disease of bone were treated with synthetic salmon calcitonin for periods of 9 to 42 months (average, 23 months). Serum alkaline phosphatase concentration and urinary hydroxyproline excretion, which had been elevated before treatment, were decreased by calcitonin treatment in all patients, and some decrease was sustained in 23 in association with variable decreases in pain, heat and stiffness of major joints. Improvement was sustained further in approximately half of these patients; the other half had partial return of symptoms. Calcium absorption was increased in 9 of 10 patients studied; the increase did not correlate with plasma concentrations of parathyroid hormone. The mean endogenous fecal calcium excretion was decreased significantly but there was no significant change in mean urinary calcium excretion. Mean accretion rate of calcium to bone, studied in 10 patients, was decreased by 35% after 6 months of treatment and by a further 23% 1 year later. There was no consistent effect of calcitonin treatment on bone mineral mass. No serious adverse effects of treatment such as allergic reactions were observed. Calcitonin appears to be effective initially in most patients with Paget''s disease of bone, but with long-term treatment resistance may be acquired.     

Renal Effects of Calcitonin

Porcine calcitonin in a slow-release gelatin vehicle was given by intramuscular injection to 10 patients—four with primary hyperparathyroidism, four with Paget''s disease, and two with carcinoma of the breast and hypercalcaemia. All cases showed a fall in serum calcium with an immediate rise in urine calcium. All except three patients with primary hyperparathyroidism showed a fall in serum phosphorus, but an immediate rise in urine phosphorus occurred in all cases. Urine hydroxyproline output fell in three patients with severe Paget''s disease. Urine sodium rose in all cases, but the effects on potassium, magnesium, water, and pH were not appreciably different from results obtained in four control subjects who were given the gelatin vehicle alone.The data suggest that calcitonin caused a decrease in the tubular resorption of calcium and phosphorus. The hypocalcaemic effect appeared to be due to a decrease in bone resorption in the patients with Paget''s disease but in the remaining cases could be accounted for in part or entirely by the rise in urine calcium.     

Effect of Actinomycin D on Paget's Disease of Bone

Four patients with active Paget''s disease were treated with the RNA inhibitor actinomycin D. Three were clinically improved after treatment; the fourth had multiple collapsed vertebrae and showed no symptomatic improvement. Striking changes took place in urinary calcium and hydroxyproline, in serum alkaline phosphatase, and to a less extent in serum calcium and phosphate. These studies are continuing and are being compared with the effects of mithramycin.     

Mithramycin therapy in Paget's disease

Nine patients with symptomatic Paget''s disease were treated with mithramycin in doses of 15 μg/kg/day for 10 days. All but one had considerable symptomatic improvement and, in some, pain relief was dramatic after only a few days. A progressive decrease in serum alkaline phosphatase levels and urinary hydroxyproline excretion was seen at the same time. Bone scans with technetium-99m stannous polyphosphate were performed in six patients and were grossly abnormal in all, showing increased uptake in areas approximately co-extensive with the radiological changes. In five cases improvement in the scans was seen during therapy. In those cases in which the scans had not returned to normal by the end of therapy the improvement continued and was associated with a further decrease in serum alkaline phosphatase levels. We suggest that mithramycin is effective therapy for Paget''s disease and, in the dose used, is safe.     

PAGET'S DISEASE—Changes Occurring Following Treatment with Newer Hormonal Agents

From experience in six cases the anabolic steroid hormones, especially long-acting testosterone and estrogen preparations, are the treatment of choice in Paget''s disease, as in postmenopausal osteoporosis. Details of the management of three patients over a period of four years are presented.Roughly 4 per cent of the population, mostly persons over 40, show some evidence of Paget''s disease. Only a small number of them, however, have severe manifestations requiring treatment, such as pain, howing or fracture of the bones, pressure on nerves or heart failure. In rare cases malignant changes occur in the involved bone.Since the cause of Paget''s disease is not known, treatment in the past has been largely empirical. Reifenstein and Albright had advocated the therapeutic use of calcium, vitamin D and ascorbic acid, and, in postmenopausal women, administration of estrogens; but with fractures or immobilization, intake of calcium-containing foods, such as milk, must be restricted to avoid dangerous piling up of calcium and kidney stones, and fluids must be forced. In recent years anabolic steroid hormones, principally oral androgens and estrogens, have been employed by Gordan and others to promote bone repair, lessen bone pain and decrease urinary excretion of calcium. While these hormones probably do not arrest the disease, they seem to stabilize it and bring relief of symptoms.More recently, Albright and Henneman demonstrated that very large doses of corticotropin (ACTH) or cortisone resulted in immediate cessation of bone pain, decrease in urinary excretion of calcium and histologic evidence of regression of the disease process. The large doses required, however, also produce dangerous side effects, such as psychosis and osteoporosis, indicating that such treatment probably should not be continued over long periods.     

Metabolic balance studies in patients with Paget's disease receiving salmon calcitonin over long periods.

Metabolic balance and calcium kinetic studies were performed in four patients with Paget''s disease before treatment with salmon calcitonin and during the early and late stages of the treatment, which lasted 9 to 19 months, A significant decrease in bone turnover and 24-hour urine hydroxyproline and serum alkaline phosphatase values was observed in all patients. In contrast, the calcium, phosphorus and magnesium balances did not change significantly. In agreement with this, the partial body calcium, measured by in vivo neutron activation analysis, did not change. Intestinal calcium absorption increased initially, but returned to baseline levels 9 to 19 months after the study began. During the initial period there was a small, significant, but transient decrease in tubular reabsorption of phosphorus; this was accompanied by a significant decrease in serum phosphorus values--probably a direct effect of calcitonin rather than evidence of secondary hyperparathyroidism. Administration of salmon calcitonin to patients with Paget''s disease decreases bone turnover without affecting calcium and phosphorus balances.     

Chronic treatment of Paget's disease of bone with synthetic human calcitonin.

Twelve patients with Paget''s disease of bone were treated with synthetic human calcitonin for seven to 26 months (mean 15.3 months). This group included six patients who had previous therapy. Eleven of the 12 patients experienced relief of the symptoms associated with Paget''s disease. The initial therapy of synthetic human calcitonin 0.5-1.0 mg subcutaneously was administered daily until the alkaline phosphatase had declined to a plateau response; the dose was then decreased to thrice weekly. The major biochemical findings were a 47 percent fall in serum alkaline phosphatase and a comparable decline in 24-hour urinary hydroxyproline. Two subjects discontinued therapy because of side effects; persistent nausea and vomiting in one and a cutaneous allergic reaction in the other. Other side effects were minor. Preliminary results suggest that some patients will maintain the same biochemical response on the reduced dose but that this is not predictable by pre-treatment data. We conclude that synthetic human calcitonin is a safe and effective treatment for Paget''s disease of bone. Preliminary results suggest that the dose and frequency of administration of this agent must be individualized.     

Direct and indirect assessment of the parathyroid hormone response to pamidronate therapy in Paget's disease of bone and hypercalcaemia of malignancy

In patients with either Paget's disease or hypercalcaemia associated with malignancy (HCM) we have assessed the parathyroid response to pamidronate therapy, both by immunoassay of serum intact parathyroid hormone PTH (1–84) and by measurement of indirect parameters of PTH bioactivity, tubular maximum reabsorption of phosphate (TmPO₄/GFR) and nephrogenous cyclic AMP (NcAMP).In 12 patients with Paget's disease, therapy with pamidronate produced a small but significant decrease in adjusted serum calcium within the reference interval which was accompanied by a progressive increase in PTH (1–84) secretion and a corresponding fall in TmPO₄/GFR and increase in NcAMP.In 12 patients with HCM pretreatment, PTH (1–84) concentrations were suppressed, whilst mean TmPO₄/GFR was reduced and NcAMP was increased, compatible in most patients, with parathyroid hormone-related peptide (PTHrP) driven hypercalcaemia. Therapy with pamidronate produced the expected fall in serum calcium but caused an increase in PTH (1–84) secretion in the presence of absolute hypercalcaemia. The initial subnormal TmPO₄/GFR decreased further to a nadir on day 5, and there was a corresponding further increase in NcAMP. By day 7, however, when PTH (1–84) concentrations were maximal, there was a significant paradoxical rise in TmPO₄/GFR and a corresponding decrease in NcAMP.These data are consistent with a variable trigger point for PTH (1–84) secretion, one consequence of which is a reduction in the risk of hypocalcaemia following pamidronate.The results have major clinical implications for the interpretation of PTH (1–84) measurements in patients who are being treated or about to be treated for bone disease or for hypercalcaemia of malignancy (HCM). A pretreatment sample is essential in making the correct diagnosis in such patients, preventing confusion and possible unnecessary investigation.     

Malabsorption Syndrome in Paget's Disease of Bone

Of eight patients with Paget''s disease one had diarrhoea, steatorrhoea, impaired xylose absorption, and macrocytic anaemia due to folic acid deficiency, while another had diarrhoea and very low xylose absorption. In both patients jejunal biopsy was normal, and they responded to folic acid therapy with considerable increase in xylose absorption. Low xylose excretion was seen in three more patients, one of whom also had steatorrhoea. Thus malabsorption may be a systemic complication of Paget''s disease of bone, possibly due either to secondary folate deficiency or to relative ischaemia of the bowel.     

Paget's Disease in a 5-year-old: Acute Response to Human Calcitonin

A five-year-old boy presented with a three-and-a-half-year history of repeated bone fractures and progressive bone deformity. The excretion of hydroxyproline in the urine was greatly increased, and serum alkaline phosphatase and acid phosphatase levels were very high. These abnormalities together with the findings on bone histology and radiology suggested a diagnosis of juvenile Paget''s disease. Human calcitonin reduced the bone turnover as evidenced by an immediate and sustained fall in urine hydroxyproline excretion, while calcium and phosphate balance became more positive. This treatment is therefore being continued on an outpatient basis.     

Paget's disease with orbital involvement: a review and case report

Paget's disease (osteitis deformans) is characterized by localized deformation of bone leading to structural abnormalities with secondary pain, fractures and nerve compression. A Paget's patient with exophthalmos, a displaced globe, restricted muscle fields, diplopia and superior oblique entrapment secondary to deformation of the frontal bone is presented. The clinical features, ocular complications and treatment of Paget's disease is discussed.     

Paget's disease of bone in 14 British towns.

The radiological prevalence of Paget''s disease was studied in 14 towns. Routine radiographs showed that the disease was present in 5.4% of people aged 55 years and over. The disease was more prevalent in men than in women at all ages, and the prevalence increased with age. The three Lancashire towns studied (Preston, Bolton, and Blackburn) had higher rates than elsewhere. This probably reflects a real geographical variation in the prevalence of Paget''s disease in England and Wales.     

Effect of calcitonin treatment on deafness due to Paget's disease of bone.

Seventeen patients with Paget''s disease of the skull and deafness were followed for nine to 18 months. Patients who received calcitonin treatment showed less deterioration in hearing than untreated patients. Calcitonin treatment may retard the progression of deafness in Paget''s disease, and further studies are indicated.     

Paget's disease of bone: the Lancashire focus.

The radiological prevalence of Paget''s disease of bone has been studied in 31 towns in Britain. A remarkably localised area of high prevalence has been shown in Lancashire. Although environmental influences seem dominant in the aetiology of the disease, no hypothesis about the environmental cause of the Lancashire focus can be advanced.     

Paget's disease of bone: early and late responses to three different modes of treatment with aminohydroxypropylidene bisphosphonate (APD).

Early and late responses to treatment with either oral (600 mg/day) or intravenous (20 mg/day) (3-amino-1-hydroxypropylidene)-1,1-bisphosphonate (aminohydroxypropylidene bisphosphonate; APD) were studied in 142 patients with Paget''s disease of bone who had not previously been treated with bisphosphonate. The efficacy of three therapeutic regimens was compared: (a) oral aminohydroxypropylidene bisphosphonate given continuously until six months after the serum alkaline phosphatase activity had returned to normal (long term); (b) oral aminohydroxypropylidene bisphosphonate given until urinary hydroxyproline excretion had returned to normal (short term); (c) intravenous aminohydroxypropylidene bisphosphonate for 10 days. With either oral or intravenous treatment the decrease in urinary hydroxyproline excretion was rapid and always preceded the fall in serum alkaline phosphatase activity. Normal urinary hydroxyproline excretion is essential for return of the serum alkaline phosphatase activity to normal. Complete biochemical remission, defined as return of the serum alkaline phosphatase activity to normal, was obtained in 129 patients (91%). The median duration of remission as assessed by actuarial analysis was 2.7 years. This study found no difference in the long term among the three modes of treatment, suggesting that for most patients with Paget''s disease a short course of intravenous aminohydroxypropylidene bisphosphonate will produce longlasting, complete remission without need for maintenance treatment.     

Aspects of Parathyroid Physiology in Mammals

This report summarizes the parameters of parathyroid physiologyin the mammal. Emphasis is given to the part played by thishormone in the processes of growth and remodelling in bone aswell as to its function in the maintenance of a relatively constantlevel of ionic calcium in the extracellular fluid. The importanceof phosphate ions has been shown, particularly with respectto their role in the rate of Ca-transport through the extracellularfluid compartments, and their influence on the rate of parathyroidsecretion. In addition, the inter-relationship of the newlydiscovered hormone, thyrocalcitonin, is considered. The latterhormone, by suppressing resorption of bone, may have an influencein stabilizing plasma levels of calcium; it also has a moderate,but long range effect on the rate of bone remodelling. Finally,an attempt has been made to relate the vast amount of work donewith these two hormones in mammals to their phylogenetic developmentin vertebrates. It is suggested that the parathyroids developedat the time when the specialization of bone in vertebrates produceda solid structure which was incompatible with the fluid calciumconcentration needed for the maintenance of many physiologicalfunctions. The parathyroid hormone, by its action to increasethe transfer of calcium from bone against a concentration gradient,permitted these vertebrates to maintain the higher fluid calciumion concentration needed for the normal functioning of the animal.     

Avian Parathyroid Physiology: Including a Special Comment on Calcitonin

During the reproductive cycle, the females of avian speciesmetabolize large amounts of calcium, deposit large amounts ofapatite in intramedullary bone, and develop hyperplastic andhypertrophied parathyroid glands. Secondary hyperparathyroidismdevelops when the amount of calcium in the diet is low. Hyperparathyroidism,either endogenous or from injections of parathyroid extract,produces resorption of endosteal bone and not mobilization ofthe deposits of intramedullary bone that normally store calciumfor calcification of the eggshell.The specificity of the siteof action of the hormone suggests that the process of mobilizationof mineral from intramedullary bone and fluctuations in thelevel of calcium in the blood are attributable not to the actionof the parathyroid hormone but indirectly to cyclical changesin the output of estrogen. Methods of measurement of calciumkinetics, parathyroid hormone-induced metabolic processes, andcellular reactions of bone cells to calcitonin should be investigatedin vitro in explants of intramedullary bone to learn more aboutthe specialized physiological characteristics of the tissue.     

Le récepteur du calcium : un rôle central dans le métabolisme calcique

The extracellular calcium-sensing receptor (CaSR) enables the parathyroid gland cells to sense the extracellular calcium concentration, to adapt the amount of parathyroid hormone secreted by those glands and, in turn, by its action on kidney and bone, to maintain steady the extracellular calcium concentration. The prominent role of CaSR is illustrated by the fact that CaSR mutations are responsible for disorders in extracellular calcium metabolism. Drugs that either activate or inactivate CaSR will open new therapeutic opportunities in several areas of mineral metabolism.     

Explanation for Unusual Potency of Salmon Calcitonin

THE calcitonins are polypeptide hormones of thirty-two amino-acids which lower serum calcium in mammals by inhibiting bone resorption¹. During evaluation of these hormones as a means of treating skeletal disorders in man, particularly Paget's disease of bone^{2, 3}, the surprising observation was made that calcitonin from the salmon (SCT) is 20–200 times more potent than porcine calcitonin (PCT) and at least ten times more potent than human calcitonin^{3, 4}. SCT is far more potent than any mammalian calcitonin yet tested in a wide variety of animal species^{5, 6}. This unusual potency of salmon calcitonin could reflect either a greater hormone affinity for receptor sites or a greater resistance to metabolic destruction. We now report evidence which supports the latter possibility, infused SCT disappears from the circulation of the dog much more slowly than does PCT.